Trandolapril 4 mg Tablet Under Fasting Conditions
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-02-10
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 40
- Registration Number
- NCT00840632
- Locations
- 🇨🇦
Biovail Contract Research, Toronto, Ontario, Canada
Meloxicam 15 mg Tablets Under Fasting Conditions
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-02-10
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 28
- Registration Number
- NCT00840476
- Locations
- 🇨🇦
Biovail Contract Research, Toronto, Ontario, Canada
Clarithromycin 500 mg Extended Release Tablets Under Non-Fasting Conditions.
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-02-10
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 22
- Registration Number
- NCT00840216
- Locations
- 🇺🇸
Gateway Medical Research Inc., Saint Charles, Missouri, United States
Cilostazol 50 mg Tablets Under Fasting Conditions
- First Posted Date
- 2009-02-10
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 30
- Registration Number
- NCT00839930
- Locations
- 🇺🇸
PRACS Institute Ltd., East Grand Forks, Minnesota, United States
🇺🇸PRACS Institute, Ltd., Fargo, North Dakota, United States
Buspirone Hydrochloride 30mg Tablets, Non-Fasting
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-02-10
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 24
- Registration Number
- NCT00840398
- Locations
- 🇺🇸
PRACS Institute, Ltd., Fargo, North Dakota, United States
Buspirone Hydrochloride 30mg Tablets, Fasting
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-02-10
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 70
- Registration Number
- NCT00840606
- Locations
- 🇺🇸
PRACS Institute, Ltd., Fargo, North Dakota, United States
Meloxicam 15 mg Tablets Under Non-Fasting Conditions
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-02-10
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 28
- Registration Number
- NCT00840879
- Locations
- 🇨🇦
Biovail Contract Research, Toronto, Ontario, Canada
600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL Suspension Under Fed Conditions
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-02-10
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 48
- Registration Number
- NCT00840840
- Locations
- 🇨🇦
Pharma Medica Research Inc., Toronto, Ontario, Canada
Trandolapril 4 mg Tablet Under Non-Fasting Conditions
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-02-10
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 50
- Registration Number
- NCT00840073
- Locations
- 🇨🇦
Pharma Medica Research Inc., Toronto, Ontario, Canada
Lamotrigine 25 mg Chewable Tablets, Fasting
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-02-06
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 32
- Registration Number
- NCT00838279
- Locations
- 🇨🇦
Anapharm Inc., Sainte-Foy, Quebec, Canada
© Copyright 2024. All Rights Reserved by MedPath